tbuckley/cabot-search huggingface dataset:
Hydroxyapatite-modified micro/nanostructured titania surfaces with different crystalline phases for osteoblast regulation
Authors: Pinliang Jiang, Yanmei Zhang, Ren Hu, Xiankuan Wang, Yuekun Lai, Gang Rui, Changjian Lin
Journal: Bioactive Materials (2020)

Surface structures and physicochemical properties critically influence osseointegration of titanium (Ti) implants. Previous studies have shown that the surface with both micro- and nanoscale roughness may provide multiple features comparable to cell dimensions and thus efficiently regulate cell-material interaction. However, less attention has been made to further optimize the physicochemical properties (e.g., crystalline phase) and to further improve the bioactivity of micro/nanostructured surfaces. Herein, micro/nanostructured titania surfaces with different crystalline phases (amorphous, anatase and anatase/rutile) were prepared and hydroxyapatite (HA) nanorods were deposited onto the as-prepared surfaces by a spin-assisted layer-by-layer assembly method without greatly altering the initial multi-scale morphology and wettability. The effects of crystalline phase, chemical composition and wettability on osteoblast response were investigated. It is noted that all the micro/nanostructured surfaces with/without HA modification presented superamphiphilic. The activities of MC3T3-E1 cells suggested that the proliferation trend on the micro/nanostructured surfaces was greatly influenced by different crystalline phases, and the highest proliferation rate was obtained on the anatase/rutile surface, followed by the anatase; but the cell differentiation and extracellular matrix mineralization were almost the same among them. After ultrathin HA modification on the micro/nanostructured surfaces with different crystalline phases, it exhibited similar proliferation trend as the original surfaces; however, the cell differentiation and extracellular matrix mineralization were significantly improved. The results indicate that the introduction of ultrathin HA to the micro/nanostructured surfaces with optimized crystalline phase benefits cell proliferation, differentiation and maturation, which suggests a favorable biomimetic microenvironment and provides the potential for enhanced implant osseointegration in vivo.
TCT CONNECT-68 Benefit-Risk Profile of DAPT Continuation Beyond 1 Year After PCI in Patients With High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline
Authors: Hao-Yu Wang, Dong Yin, Run-Lin Gao, Bo Xu, Ke-Fei Dou
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-308 Impact of High Troponin Elevation After Percutaneous Coronary Intervention for Left Main Disease: Does It Affect Patients Prognosis?
Authors: Wojciech Skorupski, Maciej Lesiak, Marek Grygier, Malgorzata Pyda, Stefan Grajek, Aleksander Araszkiewicz, Wlodzimierz Skorupski, Przemyslaw Mitkowski, Andrzej Siniawski, Stanislaw Jankiewicz, Sylwia Iwanczyk, Michał Lesiak, Marta Kaluzna-Oleksy
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-399 Role of Post-Stent Physiologic Assessment in a Risk Prediction Model After Coronary Stent Implantation
Authors: Doyeon Hwang, Joo Myung Lee, Seokhun Yang, Mineok Chang, Jinlong Zhang, Ki Hong Choi, Chee Hae Kim, Chang-Wook Nam, Eun-Seok Shin, Jae-Jin Kwak, Joon-Hyung Doh, Masahiro Hoshino, Rikuta Hamaya, Yoshihisa Kanaji, Tadashi Murai, Junjie Zhang, Fei Ye, Zhen Ge, Shao-Liang Chen, Tsunekazu Kakuta, Bon-Kwon Koo
Journal: Journal of the American College of Cardiology (2020)
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia
Authors: Mariela Sivina, Lianchun Xiao, Ekaterina Kim, Alicia Vaca, Shih-Shih Chen, Michael J. Keating, Alessandra Ferrajoli, Zeev Estrov, Nitin Jain, William G. Wierda, Xuelin Huang, Nicholas Chiorazzi, Jan A. Burger
Journal: Leukemia (2020)
Oligodendroglioma in 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT
Authors: Birgit Pernthaler, Tina Nazerani Hooshmand, Jasminka Igrec, Herbert Kvaternik, Reingard M. Aigner
Journal: Clinical Nuclear Medicine (2020)

Abstract Prostate cancer (PC) is one of the most common cancers affecting men worldwide, with a high recurrence rate after therapy. 68 Ga-PSMA-11 and 18 F-fluciclovine are PET imaging tracers for the detection of recurrence sites in PC patients. 68 Ga-PSMA-11 is a membrane antigen overexpressed by tumor cells, whereas 18 F-fluciclovine targets increased amino acid transporter in the membrane of cancer cells. We report a case of an 83-year-old man with known oligodendroglioma and biochemically recurrent PC who shows a high focal 68 Ga-PSMA-11 and 18 F-fluciclovine uptake in the brain.
Flavonoids as antiobesity agents: A review
Authors: Ana T. Rufino, Vera M. Costa, Félix Carvalho, Eduarda Fernandes
Journal: Medicinal Research Reviews (2020)

Obesity is a global health problem that affects all age groups in both developing and developed countries. In recent years, the prevalence of overweight and obesity has reached pandemic levels, resulting in a dramatic increase in the incidence of various comorbidities, such as cardiovascular diseases, type 2 diabetes, and cancer, consequently leading to massive health and socioeconomic burdens. Together with lifestyle changes, antiobesity pharmacotherapy is gaining momentum as an adjunctive treatment. However, the available pharmacological approaches have limited use owing to either significant adverse effects or low efficacy. Over the years, natural products have been an important source of lead compounds for drug discovery. Among these, flavonoids are associated with important biological effects and health-promoting activities. In this review, we discuss the modulatory effects of flavonoids on obesity and their potential mechanisms of action. The literature strongly suggests that most common flavonoids demonstrate a pronounced effect on obesity as shown by their ability to lower body weight, fat mass, and plasma triglycerides/cholesterol, both in in vitro and in vivo models. The impact of flavonoids on obesity can be observed through different mechanisms: reducing food intake and fat absorption, increasing energy expenditure, modulating lipid metabolism, or regulating gut microbiota profile. A better understanding of the known antiobesity mechanisms of flavonoids will enable their potential use to treat this medical condition. Therefore, this review focuses on the putative biological mechanisms through which flavonoids may prevent or treat obesity and highlights new perspectives on future pharmacological use.
Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer
Authors: Fang Huang, Kenneth E. Huffman, Zixi Wang, Xun Wang, Kailong Li, Feng Cai, Chendong Yang, Ling Cai, Terry S. Shih, Lauren G. Zacharias, Andrew Chung, Qian Yang, Milind D. Chalishazar, Abbie S. Ireland, C. Allison Stewart, Kasey Cargill, Luc Girard, Yi Liu, Min Ni, Jian Xu, Xudong Wu, Hao Zhu, Benjamin Drapkin, Lauren A. Byers, Trudy G. Oliver, Adi F. Gazdar, John D. Minna, Ralph J. DeBerardinis
Journal: Journal of Clinical Investigation (2020)

MYC stimulates both metabolism and protein synthesis, but how cells coordinate these complementary programs is unknown. Previous work reported that, in a subset of small-cell lung cancer (SCLC) cell lines, MYC activates guanosine triphosphate (GTP) synthesis and results in sensitivity to inhibitors of the GTP synthesis enzyme inosine monophosphate dehydrogenase (IMPDH). Here, we demonstrated that primary MYChi human SCLC tumors also contained abundant guanosine nucleotides. We also found that elevated MYC in SCLCs with acquired chemoresistance rendered these otherwise recalcitrant tumors dependent on IMPDH. Unexpectedly, our data indicated that IMPDH linked the metabolic and protein synthesis outputs of oncogenic MYC. Coexpression analysis placed IMPDH within the MYC-driven ribosome program, and GTP depletion prevented RNA polymerase I (Pol I) from localizing to ribosomal DNA. Furthermore, the GTPases GPN1 and GPN3 were upregulated by MYC and directed Pol I to ribosomal DNA. Constitutively GTP-bound GPN1/3 mutants mitigated the effect of GTP depletion on Pol I, protecting chemoresistant SCLC cells from IMPDH inhibition. GTP therefore functioned as a metabolic gate tethering MYC-dependent ribosome biogenesis to nucleotide sufficiency through GPN1 and GPN3. IMPDH dependence is a targetable vulnerability in chemoresistant MYChi SCLC.
Implantable Cardioverter Defibrillator Management at the End of Life
Authors: Samuel A. Kelly, Ryan Kabir, Neil Keshvani
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Double-stranded RNA (dsRNA) danger motif is potent adjuvant to accentuate peptide-based cancer vaccine by bridging innate and adaptive immunity.
Authors: Mohamed L. Salem, Andre Kadima, Yuehua Zhou, David J. Cole, William E. Gillanders
Journal: Cancer Research (2004)

2161  The primary response of CD8+ T cells is characterized by rapid expansion followed by contraction in which the majority of antigen-specific T cells undergo apoptosis with a diminshed memory T cell population. Recent evidence suggests that stimulation of innate immunity by inflammatory (danger) signals can augment antigen-specific CD8+ T cell responses. Polyinosinic-polycytidylic acid (Poly I:C), a viral mimic dsRNA-like polymer, is a potent inducer of innate immunity via TLR-3 receptors. Here, we investigated the impact of Poly I:C on both the expansion and contraction of antigen-specific CD8+ T cells in an OT-1 TCR transgenic mouse adoptive transfer model. Following adoptive transfer of OT-1 cells, recipient mice were primed subcutaneously with peptide (100 μg/mouse) with or without single intraperitoneal injection of Poly I:C (200 μg/mouse). We found that priming with peptide alone resulted in a transient expansion of OT-1 cells peaking on day 3 (4% in PBL) with a marked contraction thereafter. In contrast, vaccination with peptide and Poly I:C induced massive expansion of OT-1 cells peaking on day 7 (18% in PBL ) associated with a delay in T cell contraction. This was also associated with a 3-fold decrease in the number of OT-1 cells undergoing apoptosis and a ten-fold increase in the gene expression of the anti-apoptotic factors Bcl-3 and Bcl-xL. Poly I:C provided sustained activation of OT-1 cells during the priming and effector phases, as reflected by the enhanced expression of CD25, CD95, CD11b/CD11a and decreased CD62L expression. In addition, Poly I:C administration augmented effector and memory cells to produce IFN-γ and TNF-α. Timing of administration is apparently critical as Poly I:C lacked its adjuvant effects when injected two days before vaccination. Most importantly, Poly I:C along with vaccination suppressed the intraperitoneal growth of Eg.7 lymphoma (6 × 107 cells in vaccinated mice vs 1 × 107 in vaccinated and Poly I:C treated mice) and lung metastasis of B16OVA melanoma (120 colonies in vaccinated mice vs 10 colonies in vaccinated and Poly I:C treated mice). The adjuvant effects of Poly I:C were markedly reduced in the absence of NK cells or IFN-γ produced by either host or effector cells. Collectively, these results provide strong evidence that providing a danger signal during peptide vaccination can accentuate the quantity and quality of antigen-specific CD8+ T cells, establishment of long-term anti-tumor immunity.
Effective antitumor activity of 5T4‐specific CAR‐T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo
Authors: Cuiyu Guo, E Dong, Qinhuai Lai, Shijie Zhou, Guangbing Zhang, Mengdan Wu, Xiaozhu Yue, Yiran Tao, Yujia Peng, Jamel Ali, Ying Lu, Yuyin Fu, Weirong Lai, Zhixiong Zhang, Fanxin Ma, Yuqin Yao, Lantu Gou, Hanshuo Yang, Jinliang Yang
Journal: MedComm (2020)

Abstract Ovarian cancer is considered to be the most lethal gynecologic malignancy, and despite the development of conventional therapies and new therapeutic approaches, the patient's survival time remains short because of tumor recurrence and metastasis. Therefore, effective methods to control tumor progression are urgently needed. The oncofetal tumor‐associated antigen 5T4 (trophoblast glycoprotein, TPBG) represents an appealing target for adoptive T‐cell immunotherapy as it is highly expressed on the surface of various tumor cells, has very limited expression in normal tissues, and spreads widely in malignant tumors throughout their development. In this study, we generated second‐generation human chimeric antigen receptor (CAR) T cells with redirected specificity to 5T4 (5T4 CAR‐T) and demonstrated that these CAR‐T cells can elicit lytic cytotoxicity in targeted tumor cells, in addition to the secretion of cytotoxic cytokines, including IFN‐γ, IL‐2, and GM‐CSF. Furthermore, adoptive transfer of 5T4 CAR‐T cells significantly delayed tumor formation in xenografts of peritoneal and subcutaneous animal models. These results demonstrate the potential efficacy and feasibility of 5T4 CAR‐T cell immunotherapy and provide a theoretical basis for the clinical study of future immunotherapies targeting 5T4 for ovarian cancer.
Physiological and quantitative CT-scan characterization of COVID-19 and typical ARDS: a matched cohort study
Authors: Davide Chiumello, Mattia Busana, Silvia Coppola, Federica Romitti, Paolo Formenti, Matteo Bonifazi, Tommaso Pozzi, Maria Michela Palumbo, Massimo Cressoni, Peter Herrmann, Konrad Meissner, Michael Quintel, Luigi Camporota, John J. Marini, Luciano Gattinoni
Journal: Intensive Care Medicine (2020)

To investigate whether COVID-19-ARDS differs from all-cause ARDS.
Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types
Authors: Riyue Bao, Daniel Stapor, Jason J. Luke
Journal: Genome Medicine (2020)

The T cell-inflamed tumor microenvironment, characterized by CD8 T cells and type I/II interferon transcripts, is an important cancer immunotherapy biomarker. Tumor mutational burden (TMB) may also dictate response, and some oncogenes (i.e., WNT/β-catenin) are known to mediate immunosuppression.
TCT CONNECT-283 Investigation of the Association of Wall Shear Stress and Fibrous Cap Thickness Assessed by Deep Learning
Authors: David Molony, Juhwan Lee, Marina Piccinelli, Ryan Dunn, Sameer Khawaja, Kaylyn Crawford, Luis Augusto Dallan, Vladislav Zimin, Yi-An Ko, Sonali Kumar, Arnav Kumar, Sonu Gupta, Imran Shah, Jéssica Navas Simbana, Adrien Lefieux, Bill Gogas, Shao-Liang Chen, Hiromasa Otake, Takashi Akasaka, Bon-Kwon Koo, Goran Stankovic, Chang-Wook Nam, Javier Escaned, Andrejs Erglis, Eun-Seok Shin, Joo Myung Lee, Hiram Bezerra, David Wilson, Habib Samady
Journal: Journal of the American College of Cardiology (2020)
Biofunctionalized Liposomes to Monitor Rheumatoid Arthritis Regression Stimulated by Interleukin‐23 Neutralization
Authors: Ana Cláudia Lima, Cláudia F. Campos, Cristina Cunha, Agostinho Carvalho, Rui L. Reis, Helena Ferreira, Nuno M. Neves
Journal: Advanced Healthcare Materials (2020)

Abstract Even after the revolution of rheumatoid arthritis (RA) treatment with biologic agents, this debilitating disease remains a major clinical problem. The outstanding outcomes of the systemic administration of antibodies (Abs) are narrowed by the risk of serious side effects and limited efficacy due to their short half‐life. Interleukin‐23 (IL‐23) is a crucial pro‐inflammatory cytokine involved in inflammation that potently enhances the generation of T‐helper type‐17 (Th17) cells. Hence, in this work, anti‐IL‐23 Abs are immobilized at the surface of liposomes to increase their therapeutic efficacy, being gold nanoparticles (AuNPs) incorporated to allow monitoring the biodistribution of the liposomes after systemic administration as well as due to their anti‐inflammatory and antioxidant effects. A stable monodispersed liposomes’ suspension with around 130 nm is produced and efficiently biofunctionalized with anti‐IL‐23 Abs. IL‐23 capture and neutralization capacity are confirmed using activated macrophages. Biological assays demonstrate their hemocompatibility and cytocompatibility with human articular chondrocytes, macrophages, and endothelial cells. Moreover, the neutralization of IL‐23 by the biofunctionalized liposomes efficiently decreases the production of IL‐17A by peripheral blood mononuclear cells of healthy donors and RA patients who are activated to Th17 differentiation. Therefore, the developed formulation may be a promising strategy to treat RA.
TCT CONNECT-234 Impact of Chronic Total Occlusion Revascularization on Left Ventricular Function Assessed by Cardiac Magnetic Resonance
Authors: Michael Megaly, Emmanouil Brilakis, Mahmoud Abdelsalam, Ashish Pershad, Marwan Saad, Santiago Garcia, M. Nicholas Burke, Eric Schelbert, Chiara Bucciarelli-Ducci, Joao Cavalcante - DUPE
Journal: Journal of the American College of Cardiology (2020)
Expanded Low Allele Frequency <i>RAS</i> and <i>BRAF</i> V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial
Authors: Jonathan M. Loree, Anthony Dowers, Dongsheng Tu, Derek J. Jonker, Daniel L. Edelstein, Hannah Quinn, Frank Holtrup, Timothy Price, John R. Zalcberg, Malcolm J. Moore, Christos S. Karapetis, Chris J. O'Callaghan, Paul Waring, Hagen F. Kennecke, Stanley R. Hamilton, Scott Kopetz
Journal: Clinical Cancer Research (2020)

Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC), and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab efficacy in optimally selected patients using highly sensitive beads, emulsion, amplification, and magnetics (BEAMing) analysis, capable of detecting alterations below standard clinical assays.CO.17 trial compared cetuximab versus best supportive care (BSC) in RAS/BRAF-unselected mCRC. We performed RAS/BRAF analysis on microdissected tissue of 242 patients in CO.17 trial using BEAMing for KRAS/NRAS (codons 12/13/59/61/117/146) and BRAF V600E. Patients without BEAMing but with previous Sanger sequencing-detected mutations were included.KRAS, NRAS, and BRAF mutations were present in 53%, 4%, and 3% of tumors, respectively. Cetuximab improved overall survival [OS; HR, 0.51; 95% confidence interval (CI), 0.32-0.81; P = 0.004] and progression-free survival (PFS; HR, 0.25; 95% CI, 0.15-0.41; P < 0.0001) compared with BSC in RAS/BRAF wild-type patients. Cetuximab did not improve OS/PFS for KRAS-, NRAS-, or BRAF-mutated tumors, and tests of interaction confirmed expanded KRAS (P = 0.0002) and NRAS (P = 0.006) as predictive, while BRAF mutations were not (P = 0.089). BEAMing identified 14% more tumors as RAS mutant than Sanger sequencing, and cetuximab lacked activity in these patients. Mutations at MAF < 5% were noted in 6 of 242 patients (2%). One patient with a KRAS A59T mutation (MAF = 2%) responded to cetuximab. More NRAS than KRAS mutations were low MAF (OR, 20.50; 95% CI, 3.88-96.85; P = 0.0038).We establish single-agent cetuximab efficacy in optimally selected patients and show that subclonal RAS/BRAF alterations are uncommon and remain of indeterminate significance.
Scorpion Sting With ST-Segment Elevation
Authors: Himmatrao Bawaskar, Pratap Patare, Parag Bawaskar
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer
Authors: Dongxu Wang, Samuel Seery, Haitao Zhao
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
A Randomised, Double-Blind, Dose Ranging Clinical Trial of Intravenous FDY-5301 in Acute STEMI Patients Undergoing Primary PCI: The CAMPFIRE (CArdiac Muscle Preservation Following Ischemia REperfusion) Study
Authors: D Adlam, N Uren, K Oldroyd, S Munir, A Sharp, A Zaman, H Contractor, R Kiss, I Edes, M J Garcia, P Musialek, J Tomcsanyi, P Ptaszynski, G Nagy, J Szachniewicz, L Siegel, C Shirodaria, J B Selvanayagam, S Tulloch, K M Channon, C Investigators
Journal: Circulation (2019)
TCT CONNECT-207 FFR Saline by Continuous Thermodilution Infusion
Authors: Alejandro Gutierrez-Barrios, Fernando Rivero, Josep Gomez Lara, Elena Izaga-Torralba, Dolores Cañadas, Etel Silva, Livia L. Gheorghe, Ricardo De Zayas Rueda, Rafael Vázquez-García, German Calle Perez, Fernando Alfonso
Journal: Journal of the American College of Cardiology (2020)